Amphastar Pharmaceuticals
Update in progressAMPH (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Amphastar Pharmaceuticals, Inc. is a Rancho Cucamonga, California–based biopharmaceutical company that develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal products for the United States, China, and France. Its portfolio includes emergency and diagnostic injectables (BAQSIMI, Glucagon kit, Cortrosyn), asthma/allergy products (Primatene MIST, Epinephrine, Albuterol, Ipratropium), anticoagulants, opioids antidotes, and insulin APIs. Founded 1996.
Company score
- Sentiment
- 0.44
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.25
- Governance
- 0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!